Articles by admin

(Bloomberg) — Carl Icahn plans to nominate a slate of 10 directors in an attempt to seize control of the board of U.S. oil and gas producer Occidental Petroleum Corp., according to people familiar with the matter.The billionaire investor, who owns a stake in the company valued at about $1 billion, plans to make his move before the Nov. 29 deadline for nominations, said the people, who asked not to be identified because the matter is private.A representative for Icahn declined to comment, while a representative for Occidental wasn’t immediately available for comment.Icahn has been a vocal critic of the …read more […]

NEW YORK/BANGALORE (Reuters) – SoftBank Group Corp will this week launch a previously agreed tender offer for as much as $3 billion of WeWork shares, including up to $970 million owned by the office sharing company’s cofounder Adam Neumann, two people familiar with the matter said. The tender offer to the founders, investors and employees owning stock was expected to launch earlier this month but was delayed after SoftBank sought technical revisions to the offer documents, according to the sources. Last Thursday, Bloomberg reported that executives at SoftBank, the giant Japanese technology investment company, had been looking …read more […]

Is Himax Technologies, Inc. (NASDAQ:HIMX) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […] …read more […]

The Medicines Company is developing a treatment for “bad” cholesterol. …read more […]

Stocks are volatile, but not actually risky Continue reading… …read more […]

These companies have a low financial burden Continue reading… …read more […]

It’s no secret that health care costs continue to rise, and new research from the Commonwealth Fund (TCF) indicates that Americans are paying more for their premiums and deductibles than ever before. …read more […]

One exec called the alliance “a complete game-changer for the industry.” …read more […]

Novartis AG is buying U.S. biotechnology company The Medicines Co for about $9.7 billion, the Swiss drugmaker said on Sunday, as it seeks to expand its portfolio of medicines against cardiovascular disease. Novartis is paying $85 per share in cash, an approximately 24% premium over The Medicines Co.’s closing share price of $68.55 on Nov. 22. New Jersey-based The Medicines Co’s top drug candidate is cholesterol-lowering drug inclisiran for heart patients, which could complement Novartis’s growing business with its heart-failure medicine Entresto, a slow-seller to start that has now crossed the $1 billion annual revenue threshold. …read more […]

Novartis AG is buying U.S. biotechnology company The Medicines Co for about $9.7 billion, the Swiss drugmaker said on Sunday, as it seeks to expand its portfolio of medicines against cardiovascular disease. Novartis is paying $85 per share in cash, an approximately 24% premium over The Medicines Co.’s closing share price of $68.55 on Nov. 22. New Jersey-based The Medicines Co’s top drug candidate is cholesterol-lowering drug inclisiran for heart patients, which could complement Novartis’s growing business with its heart-failure medicine Entresto, a slow-seller to start that has now crossed the $1 billion annual revenue threshold. …read more […]

The company is holding on to a record amount of liquid assets, which serves as a warning for investors Continue reading… …read more […]